GSK's Camlipixant met the primary endpoint in the Calm-1 trial, but the Calm-2 trial failed to show statistical significance on the same endpoint.
FirstSquawk07/17, 03:33 PM
Related assets
Coming up for GSK
Explore next
Latest GSK news
WSJ07/29, 07:12 PM
WSJ Markets publishes a Health Care Market Talk roundup covering Argenx, GSK, and EssilorLuxottica.
WSJ07/17, 11:43 PM
FirstSquawk07/17, 10:53 AM
Jefferies resumes coverage of GSK with a Buy rating and a price target of 2,500 pence.